PRRT2 and cancer: While autophosphorylation by GSK-3 at its Y216 residue cannot be ruled out in certain conditions, at least in cancer cells, where kinases such as Akt and PKC are hyper-activated, sustaining GSK-3 activity can happen only with the existence of an alternate pathway, potentially involving a non-receptor tyrosine kinase.